OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lee on the Impact of Immunotherapy in Head and Neck Cancer

June 14th 2017

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL

June 13th 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses the outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) and how ibrutinib (Imbruvica) targets these patients.

Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

June 13th 2017

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Dr. Apolo on Immunotherapy Combinations With Cabozantinib in Genitourinary Tumors

June 13th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses immunotherapy combinations with cabozantinib (Cometriq) in genitourinary tumors.

Dr. Ferris Discusses the RTOG 3504 Study in Head and Neck Cancer

June 13th 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the RTOG 3504 study in head and neck cancer.

Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma

June 12th 2017

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Dr. Hamlin on Early Study of Ibrutinib/Buparlisib in MCL, FL, and DLBCL

June 12th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Leath on Ongoing Trials for Endometrial Cancer

June 9th 2017

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma

June 9th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

Dr. Flinn on 5-Year Follow-up of BRIGHT Study in MCL and iNHL

June 9th 2017

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses 5-year follow-up of the BRIGHT study, which explored the combination of bendamustine and rituximab (BR) versus R-CHOP/R-CVP as a first-line treatment for patients with mantle cell lymphoma (MCL) or indolent non-Hodgkin lymphoma (iNHL).

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

June 9th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

Dr. Arend on Personalized Medicine for Endometrial Cancer

June 9th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

Dr. Bekaii-Saab on Results of the IDEA Project for Colon Cancer

June 9th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the results of the phase III IDEA project for patients with stage III colon cancer.

Dr. Choueiri on Avelumab Plus Axitinib in mRCC

June 8th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

Dr. Kelley on the Development of Biomarkers for HCC

June 8th 2017

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

Dr. Rai on the Treatment Paradigm for CLL

June 8th 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).

Dr. Shah on Risk Factors for Early-Onset CRC

June 8th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).

Dr. Grignani on the Future of Treatments for Sarcoma

June 8th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

June 6th 2017

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

Dr. Loeb on Tests for the Management of Prostate Cancer

June 6th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses test options to determine the management of patients newly diagnosed with prostate cancer.